InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
57,346.41
(
1.23%
)
Post# of 12660
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

ocyanblue

Send PM Follow Ignore
Followers 0
Posts 167
Boards Moderated 0
Alias Born 03/28/2005

ocyanblue

Re: walldiver post# 936

Friday, 09/08/2006 7:54:10 AM

Friday, September 08, 2006 7:54:10 AM

Post# of 12660
"it's likely that patients will just choose to get Provenge earlier in the disease cycle, then get booster reinfusions later on."

Management clearly have this mind. The term "frontline" was mentioned a few times in the presentation.

Did anyone notice the statement on "numerous scientific presentations" in 4Q. Aside from the CD54 data and possibly a paper on the synergy of Provenge+chemo, what else could they present with the 9901+2a data?
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up